Details of the Drug

General Information of Drug (ID: DMHP21E)

Drug Name
Hydromorphone
Synonyms
hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1]
Chronic pain MG30 Phase 3 [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 285.34
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 9 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 60% [3]
Clearance
The sytemic clearance of drug is 1.96 L/min [5]
Elimination
The elimination of the parent compound represents 7% of the urine elimination and 1% of the fecal elimination [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [3]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.20158 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.86% [7]
Vd
The volume of distribution (Vd) of drug is 4 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [4]
Chemical Identifiers
Formula
C17H19NO3
IUPAC Name
(4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Canonical SMILES
CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
InChIKey
WVLOADHCBXTIJK-YNHQPCIGSA-N
Cross-matching ID
PubChem CID
5284570
ChEBI ID
CHEBI:5790
CAS Number
466-99-9
DrugBank ID
DB00327
TTD ID
D04JHN
INTEDE ID
DR0833
ACDINA ID
D00315

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Binder [8]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Inhibitor [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [13]
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Opioid receptor delta (OPRD1) DTT OPRD1 5.52E-01 0.03 0.23
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.83E-01 2.32E-03 1.53E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hydromorphone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentazocine DM1XBHS Major Additive hypotensive effects by the combination of Hydromorphone and Pentazocine. Pain [MG30-MG3Z] [80]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Hydromorphone and Dextropropoxyphene. Pain [MG30-MG3Z] [81]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Hydromorphone and Butorphanol. Pain [MG30-MG3Z] [80]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Hydromorphone and Oxymorphone. Pain [MG30-MG3Z] [82]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Hydromorphone and Levorphanol. Pain [MG30-MG3Z] [82]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Hydromorphone and Dezocine. Pain [MG30-MG3Z] [80]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Hydromorphone and Flavoxate. Pain [MG30-MG3Z] [83]
Nalbuphine DMOSQGU Major Additive hypotensive effects by the combination of Hydromorphone and Nalbuphine. Pain [MG30-MG3Z] [80]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Hydromorphone and Buprenorphine. Pain [MG30-MG3Z] [80]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Hydromorphone and Hydrocodone. Pain [MG30-MG3Z] [82]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Hydromorphone and Meperidine. Pain [MG30-MG3Z] [82]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Hydromorphone and Oxycodone. Pain [MG30-MG3Z] [82]
⏷ Show the Full List of 12 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Hydromorphone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Hydromorphone and Oliceridine. Acute pain [MG31] [82]
Chlorzoxazone DMCYVDT Major Additive CNS depression effects by the combination of Hydromorphone and Chlorzoxazone. Acute pain [MG31] [82]
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Hydromorphone and Scopolamine. Addictive disorder [6C50-6C5Z] [84]
Buspirone DMBS632 Major Additive CNS depression effects by the combination of Hydromorphone and Buspirone. Anxiety disorder [6B00-6B0Z] [82]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Hydromorphone and Clorazepate. Anxiety disorder [6B00-6B0Z] [85]
Alprazolam DMC7XDN Major Additive CNS depression effects by the combination of Hydromorphone and Alprazolam. Anxiety disorder [6B00-6B0Z] [82]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Hydromorphone and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [85]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Hydromorphone and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [82]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Hydromorphone and Halazepam. Anxiety disorder [6B00-6B0Z] [82]
Chlordiazepoxide DMTN5XI Major Additive CNS depression effects by the combination of Hydromorphone and Chlordiazepoxide. Anxiety disorder [6B00-6B0Z] [82]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Hydromorphone and Chlormezanone. Anxiety disorder [6B00-6B0Z] [82]
Clobazam - Lundbeck DMW1OQ0 Major Additive CNS depression effects by the combination of Hydromorphone and Clobazam - Lundbeck. Anxiety disorder [6B00-6B0Z] [82]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Hydromorphone and Oxazepam. Anxiety disorder [6B00-6B0Z] [82]
Promazine DMZAL7W Major Additive CNS depression effects by the combination of Hydromorphone and Promazine. Appearance/behaviour symptom [MB23] [82]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Hydromorphone and Desipramine. Attention deficit hyperactivity disorder [6A05] [86]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Hydromorphone and Cariprazine. Bipolar disorder [6A60] [82]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Hydromorphone and Loperamide. Bowel habit change [ME05] [87]
Secobarbital DM14RF5 Major Additive CNS depression effects by the combination of Hydromorphone and Secobarbital. Chronic insomnia [7A00] [82]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Hydromorphone and Dihydrocodeine. Chronic pain [MG30] [85]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Hydromorphone and Levomilnacipran. Chronic pain [MG30] [86]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Hydromorphone and Olopatadine. Conjunctiva disorder [9A60] [88]
Propofol DMB4OLE Moderate Additive cardiorespiratory depression effects by the combination of Hydromorphone and Propofol. Corneal disease [9A76-9A78] [89]
Methadone DMTW6IU Major Additive CNS depression effects by the combination of Hydromorphone and Methadone. Cough [MD12] [82]
Dextromethorphan DMUDJZM Moderate Additive CNS depression effects by the combination of Hydromorphone and Dextromethorphan. Cough [MD12] [86]
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Hydromorphone and Ethanol. Cystitis [GC00] [90]
Sertraline DM0FB1J Moderate Additive serotonergic effects by the combination of Hydromorphone and Sertraline. Depression [6A70-6A7Z] [86]
Trimipramine DM1SC8M Moderate Additive CNS depression effects by the combination of Hydromorphone and Trimipramine. Depression [6A70-6A7Z] [86]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Hydromorphone and Cyclobenzaprine. Depression [6A70-6A7Z] [82]
Imipramine DM2NUH3 Moderate Additive serotonergic effects by the combination of Hydromorphone and Imipramine. Depression [6A70-6A7Z] [86]
Fluoxetine DM3PD2C Moderate Additive CNS depression effects by the combination of Hydromorphone and Fluoxetine. Depression [6A70-6A7Z] [86]
Nortriptyline DM4KDYJ Moderate Additive serotonergic effects by the combination of Hydromorphone and Nortriptyline. Depression [6A70-6A7Z] [86]
Vilazodone DM4LECQ Moderate Additive CNS depression effects by the combination of Hydromorphone and Vilazodone. Depression [6A70-6A7Z] [86]
Nefazodone DM4ZS8M Moderate Additive serotonergic effects by the combination of Hydromorphone and Nefazodone. Depression [6A70-6A7Z] [86]
Paroxetine DM5PVQE Moderate Additive serotonergic effects by the combination of Hydromorphone and Paroxetine. Depression [6A70-6A7Z] [86]
Vortioxetine DM6F1PU Moderate Additive CNS depression effects by the combination of Hydromorphone and Vortioxetine. Depression [6A70-6A7Z] [86]
Duloxetine DM9BI7M Moderate Additive CNS depression effects by the combination of Hydromorphone and Duloxetine. Depression [6A70-6A7Z] [86]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Hydromorphone and Milnacipran. Depression [6A70-6A7Z] [86]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Hydromorphone and Desvenlafaxine. Depression [6A70-6A7Z] [86]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Hydromorphone and OPC-34712. Depression [6A70-6A7Z] [82]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Hydromorphone and Clomipramine. Depression [6A70-6A7Z] [86]
Trazodone DMK1GBJ Moderate Additive CNS depression effects by the combination of Hydromorphone and Trazodone. Depression [6A70-6A7Z] [86]
Amoxapine DMKITQE Moderate Additive CNS depression effects by the combination of Hydromorphone and Amoxapine. Depression [6A70-6A7Z] [86]
Mirtazapine DML53ZJ Moderate Additive serotonergic effects by the combination of Hydromorphone and Mirtazapine. Depression [6A70-6A7Z] [86]
Protriptyline DMNHTZI Moderate Additive serotonergic effects by the combination of Hydromorphone and Protriptyline. Depression [6A70-6A7Z] [86]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Hydromorphone and Doxepin. Depression [6A70-6A7Z] [86]
Maprotiline DMPWB7T Moderate Additive serotonergic effects by the combination of Hydromorphone and Maprotiline. Depression [6A70-6A7Z] [86]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Hydromorphone and Esketamine. Depression [6A70-6A7Z] [91]
Hyoscyamine DM804UR Moderate Additive antimotility effects by the combination of Hydromorphone and Hyoscyamine. Digestive system disease [DE2Z] [84]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Hydromorphone and Mepenzolate. Digestive system disease [DE2Z] [84]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive CNS depression effects by the combination of Hydromorphone and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [86]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Hydromorphone and Oxybutynine. Discovery agent [N.A.] [84]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Hydromorphone and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [85]
Trihexyphenidyl DMB19L8 Moderate Additive CNS depression effects by the combination of Hydromorphone and Trihexyphenidyl. Dystonic disorder [8A02] [92]
Fenfluramine DM0762O Moderate Additive CNS depression effects by the combination of Hydromorphone and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [86]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Hydromorphone and Diazepam. Epilepsy/seizure [8A61-8A6Z] [82]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Hydromorphone and Primidone. Epilepsy/seizure [8A61-8A6Z] [82]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Hydromorphone and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [93]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Hydromorphone and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [82]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Hydromorphone and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [82]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Hydromorphone and Dantrolene. Fever [MG26] [82]
Solifenacin DMG592Q Moderate Additive CNS depression effects by the combination of Hydromorphone and Solifenacin. Functional bladder disorder [GC50] [84]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Hydromorphone and Tolterodine. Functional bladder disorder [GC50] [84]
Darifenacin DMWXLYZ Moderate Additive antimotility effects by the combination of Hydromorphone and Darifenacin. Functional bladder disorder [GC50] [83]
Propantheline DM2EN6G Moderate Additive CNS depression effects by the combination of Hydromorphone and Propantheline. Gastric ulcer [DA60] [84]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Hydromorphone and Brimonidine. Glaucoma [9C61] [94]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Hydromorphone and Belladonna. Infectious gastroenteritis/colitis [1A40] [83]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Hydromorphone and Suvorexant. Insomnia [7A00-7A0Z] [82]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Hydromorphone and Amobarbital. Insomnia [7A00-7A0Z] [82]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Hydromorphone and Ramelteon. Insomnia [7A00-7A0Z] [82]
Eszopiclone DM8RZ9H Major Additive CNS depression effects by the combination of Hydromorphone and Eszopiclone. Insomnia [7A00-7A0Z] [82]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Hydromorphone and Flurazepam. Insomnia [7A00-7A0Z] [82]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Hydromorphone and Triazolam. Insomnia [7A00-7A0Z] [82]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Hydromorphone and Zaleplon. Insomnia [7A00-7A0Z] [82]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Hydromorphone and Propiomazine. Insomnia [7A00-7A0Z] [82]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Hydromorphone and Tasimelteon. Insomnia [7A00-7A0Z] [82]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Hydromorphone and Paraldehyde. Insomnia [7A00-7A0Z] [82]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Hydromorphone and ITI-007. Insomnia [7A00-7A0Z] [82]
Zolpidem DMWOSKJ Major Additive CNS depression effects by the combination of Hydromorphone and Zolpidem. Insomnia [7A00-7A0Z] [82]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Hydromorphone and Quazepam. Insomnia [7A00-7A0Z] [82]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Hydromorphone and Estazolam. Insomnia [7A00-7A0Z] [82]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Hydromorphone and Polyethylene glycol. Irritable bowel syndrome [DD91] [95]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Hydromorphone and Clidinium. Irritable bowel syndrome [DD91] [83]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Hydromorphone and Dicyclomine. Irritable bowel syndrome [DD91] [83]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Hydromorphone and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [82]
Meprobamate DMHM93Y Major Additive CNS depression effects by the combination of Hydromorphone and Meprobamate. Malaria [1F40-1F45] [82]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Hydromorphone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [96]
Almogran DM7I64Z Moderate Additive CNS depression effects by the combination of Hydromorphone and Almogran. Migraine [8A80] [86]
Frovatriptan DM7RE8P Moderate Additive CNS depression effects by the combination of Hydromorphone and Frovatriptan. Migraine [8A80] [86]
Rizatriptan DMDJMA3 Moderate Additive CNS depression effects by the combination of Hydromorphone and Rizatriptan. Migraine [8A80] [86]
Naratriptan DMO50U2 Moderate Additive serotonergic effects by the combination of Hydromorphone and Naratriptan. Migraine [8A80] [86]
Sumatriptan DMVYXR8 Moderate Additive CNS depression effects by the combination of Hydromorphone and Sumatriptan. Migraine [8A80] [86]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Hydromorphone and Lasmiditan. Migraine [8A80] [97]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Hydromorphone and Flibanserin. Mood disorder [6A60-6E23] [98]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Hydromorphone and Thalidomide. Multiple myeloma [2A83] [99]
Carisoprodol DMWR1JC Major Additive CNS depression effects by the combination of Hydromorphone and Carisoprodol. Musculoskeletal disorder [FA00-FC0Z] [82]
Prasugrel DM7MT6E Moderate Altered absorption of Hydromorphone due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [100]
Droperidol DM0DXA8 Major Additive cardiorespiratory depression effects by the combination of Hydromorphone and Droperidol. Nausea/vomiting [MD90] [101]
Palonosetron DMBHMOX Moderate Additive serotonergic effects by the combination of Hydromorphone and Palonosetron. Nausea/vomiting [MD90] [86]
Metoclopramide DMFA5MY Moderate Additive antimotility effects by the combination of Hydromorphone and Metoclopramide. Nausea/vomiting [MD90] [102]
Granisetron DMIUW25 Moderate Additive CNS depression effects by the combination of Hydromorphone and Granisetron. Nausea/vomiting [MD90] [86]
Dolasetron DMMG26Z Moderate Additive CNS depression effects by the combination of Hydromorphone and Dolasetron. Nausea/vomiting [MD90] [86]
Ondansetron DMOTQ1I Moderate Additive serotonergic effects by the combination of Hydromorphone and Ondansetron. Nausea/vomiting [MD90] [86]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Hydromorphone and Bupropion. Nicotine use disorder [6C4A] [103]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Hydromorphone and Sibutramine. Obesity [5B80-5B81] [86]
Dexfenfluramine DMJ7YDS Moderate Additive serotonergic effects by the combination of Hydromorphone and Dexfenfluramine. Obesity [5B80-5B81] [86]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Hydromorphone and Apraclonidine. Optic nerve disorder [9C40] [94]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Hydromorphone and Biperiden. Parkinsonism [8A00] [92]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Hydromorphone and Procyclidine. Parkinsonism [8A00] [92]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Hydromorphone and Pimavanserin. Parkinsonism [8A00] [82]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Hydromorphone and Orphenadrine. Parkinsonism [8A00] [82]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Hydromorphone and Lindane. Pediculosis [1G00] [104]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Hydromorphone and Methylscopolamine. Peptic ulcer [DA61] [84]
Fluphenazine DMIT8LX Major Additive CNS depression effects by the combination of Hydromorphone and Fluphenazine. Psychotic disorder [6A20-6A25] [105]
Triflupromazine DMKFQJP Major Additive CNS depression effects by the combination of Hydromorphone and Triflupromazine. Psychotic disorder [6A20-6A25] [82]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Hydromorphone and Quetiapine. Schizophrenia [6A20] [106]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Hydromorphone and Mesoridazine. Schizophrenia [6A20] [106]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Hydromorphone and Thioridazine. Schizophrenia [6A20] [82]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Hydromorphone and Aripiprazole. Schizophrenia [6A20] [82]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Hydromorphone and Iloperidone. Schizophrenia [6A20] [82]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Hydromorphone and Paliperidone. Schizophrenia [6A20] [82]
Loxapine DM8AI9U Major Additive CNS depression effects by the combination of Hydromorphone and Loxapine. Schizophrenia [6A20] [106]
Haloperidol DM96SE0 Major Additive CNS depression effects by the combination of Hydromorphone and Haloperidol. Schizophrenia [6A20] [82]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Hydromorphone and Perphenazine. Schizophrenia [6A20] [82]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Hydromorphone and Molindone. Schizophrenia [6A20] [82]
Chlorpromazine DMBGZI3 Major Additive CNS depression effects by the combination of Hydromorphone and Chlorpromazine. Schizophrenia [6A20] [105]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Hydromorphone and Thiothixene. Schizophrenia [6A20] [106]
Clozapine DMFC71L Major Additive CNS depression effects by the combination of Hydromorphone and Clozapine. Schizophrenia [6A20] [105]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Hydromorphone and Trifluoperazine. Schizophrenia [6A20] [82]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Hydromorphone and Risperidone. Schizophrenia [6A20] [82]
Olanzapine DMPFN6Y Major Additive CNS depression effects by the combination of Hydromorphone and Olanzapine. Schizophrenia [6A20] [106]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Hydromorphone and Asenapine. Schizophrenia [6A20] [82]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Hydromorphone and Pimozide. Schizophrenia [6A20] [82]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Hydromorphone and Fentanyl. Sensation disturbance [MB40] [82]
Brilinta DMBR01X Moderate Altered absorption of Hydromorphone due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [100]
Clopidogrel DMOL54H Moderate Altered absorption of Hydromorphone due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [100]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Hydromorphone and Tizanidine. Tonus and reflex abnormality [MB47] [82]
Atropine DMEN6X7 Moderate Additive antimotility effects by the combination of Hydromorphone and Atropine. Unspecific substance harmful effect [NE6Z] [83]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Hydromorphone and Cetirizine. Vasomotor/allergic rhinitis [CA08] [107]
⏷ Show the Full List of 138 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium metabisulfite E00444 656671 Antimicrobial preservative; Antioxidant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Hydromorphone 2 mg tablet 2 mg Oral Tablet Oral
Hydromorphone 4 mg tablet 4 mg Oral Tablet Oral
Hydromorphone 8 mg tablet 8 mg Oral Tablet Oral
Hydromorphone 24 mg capsule 24 mg 24 HR Extended Release Capsule Oral
Hydromorphone 16 mg tablet 16 mg 24 HR Extended Release Oral Tablet Oral
Hydromorphone 12 mg tablet 12 mg 24 HR Extended Release Oral Tablet Oral
Hydromorphone 8 mg tablet 8 mg 24 HR Extended Release Oral Tablet Oral
Hydromorphone 32 mg tablet 32 mg 24 HR Extended Release Oral Tablet Oral
Hydromorphone 12 mg capsule 12 mg 24 HR Extended Release Capsule Oral
Hydromorphone 16 mg capsule 16 mg 24 HR Extended Release Capsule Oral
Hydromorphone 32 mg capsule 32 mg 24 HR Extended Release Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Hydromorphone .
4 BDDCS applied to over 900 drugs
5 Perlman R, Giladi H, Brecht K, Ware MA, Hebert TE, Joseph L, Shir Y: Intradialytic clearance of opioids: methadone versus hydromorphone. Pain. 2013 Dec;154(12):2794-800. doi: 10.1016/j.pain.2013.08.015. Epub 2013 Aug 20.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
9 Clinical pipeline report, company report or official report of signaturerx.
10 Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57.
11 Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
12 Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.;
13 Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012 Jan;50(1):1-14.
14 Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
25 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
26 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
27 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
28 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
29 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
30 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
31 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
32 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
33 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
34 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
35 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
36 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
37 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
38 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
39 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
40 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
41 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
42 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
43 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
44 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
45 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
46 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
47 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
48 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
49 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
50 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
51 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
52 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
53 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
54 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
55 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
56 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
57 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
58 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
59 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
60 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
61 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
62 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
63 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
64 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
65 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
66 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
67 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
68 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
69 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
70 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
71 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
72 Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
73 Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
74 Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
75 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
76 Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
77 Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
78 Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
79 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
80 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
81 Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
82 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
83 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
84 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
85 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
86 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
87 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
88 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
89 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
90 Levine B, Saady J, Fierro M, Valentour J "A hydromorphone and ethanol fatality." J Forensic Sci 29 (1984): 655-9. [PMID: 6202821]
91 Cerner Multum, Inc. "Australian Product Information.".
92 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
93 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
94 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
95 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
96 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
97 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
98 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
99 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
100 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
101 Canadian Pharmacists Association.
102 Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
103 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
104 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
105 Cerner Multum, Inc. "Canadian Product Information.".
106 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
107 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.